Treatment trials for Ebola strain behind Congo outbreak show promise, WHO says

The World Health Organization reports rapid advancement in testing experimental treatments and vaccines for the Bundibugyo strain of Ebola in the Democratic Republic of Congo.

​Testing of experimental treatments, preventive ​medicines and vaccines ‌for the ​Bundibugyo strain of Ebola behind Democratic Republic of Congo's ongoing outbreak is advancing rapidly, ‌the U.N.'s World Health Organization said on Tuesday.

The epidemic — the second-largest and fastest-spreading on record — was caused by the rare Bundibugyo strain ‌of the virus, for which there are no approved ‌vaccines or treatments. But Vasee Moorthy, acting head of WHO's R&D Blueprint programme, told journalists in Geneva that research protocols developed before the epidemic's onset ⁠have helped ​speed up testing ⁠of new treatments.

"If you compare this outbreak to previous Ebola outbreaks, we ⁠have been able to start trials more quickly," he said. "It's true ​that the preclinical data that we're seeing is promising." He ⁠cautioned, however, that only clinical trials could determine whether treatments and vaccines are ⁠effective.

The ​epidemic in Congo has so far defied health workers' efforts to contain it. As of August 1, Congo had ⁠recorded 3,748 confirmed cases and 1,657 confirmed deaths across 49 health ⁠zones in ⁠five provinces, according to WHO data. About 17,000 contacts are under monitoring, with roughly 80% checked ‌daily.